Merck & Co. Inc. closed 41.34% below its 52-week high of $134.63, which the company achieved on June 25th.

Merck is growing pharma sales and expanding margins, led by strong KEYTRUDA performance and cost discipline. Read more about ...

We recently compiled a list of Billionaire Prem Watsa’s 10 Stock Picks With Highest Potential. In this article, we are going ...

Having access to the largest potential shareholder pool in the world is a major step forward in our planned marketing strategy that will focus on our German, Canadian and USA symbols. With a tight ...

Merck MRK will report its first-quarter 2024 earnings on April 24, before market open. The Zacks Consensus Estimate for first ...

Merck (NYSE:MRK) has reached a licensing agreement worth nearly $2B with the Chinese drugmaker Jiangsu Hengrui Pharmaceuticals to jointly develop and commercialize an experimental heart disease ...

Merck recently experienced a significant corporate governance event when multiple shareholder proposals were announced, with the company recommending against them for the upcoming annual meeting.

Merck & Co. is handing over $200 million to China’s Hengrui Pharma for a phase 2-stage lipoprotein(a) (Lp(a)) inhibitor. In return for the ex-China rights to the drug, dubbed HRS-5346, Merck has ...

Merck & Co. will pay as much as $2 billion for the rights to Jiangsu Hengrui Pharmaceuticals Co.’s experimental heart drug, the US drugmaker’s second recent foray into China for a novel medicine.

Under terms of the deal, Merck will gain global rights to develop, manufacture, and commercialize HRS-5346 for cardiovascular disease, excluding Greater China. Merck has entered an exclusive licensing ...

March 25 (Reuters) - Merck (MRK.N), opens new tab has signed a licensing agreement for a heart disease drug with Jiangsu Hengrui Pharmaceuticals (600276.SS), opens new tab worth up to $2 billion ...